Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Cetuximab Approved for First-Line Treatment of Head and Neck Cancer in Europe - (DGNews)
    Stromal Gene Signatures in Large-B-Cell Lymphomas - (N Engl J Med)
    Variations in Gene Activity Can Predict the Survival of Patients With Lymphoma - (DGNews)
    Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis - (JAMA)
    NICE Issues Final Guidance on the Use of Erlotinib for the Treatment of NSCLC - (DGNews)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
      Diabetes: Treatment of Type 2 Diabetes and the Role of Insulin
      Cases in Cardiology: Complications Associated with Heparin Therapy
      Aggressive Management of Type 2 Diabetes to Prevent Macrovascular Complications
      Asthma Treatment Guidelines and Use of Inhalers
      Use of Probiotics in the Management of Antibiotic-associated Diarrhea

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Experience with Adjuvant Chemotherapy for Pseudomyxoma Peritonei Secondary to Mucinous Adenocarcinoma of the Appendix with Oxaliplatin / Fluorouracil /Leucovorin (FOLFOX4)
        Recognition and Treatment of Serotonin Syndrome
        Is Enoxaparin Injection from the Abdominal Wall Safe in Elderly People?: A Fatal Case of Rectus Sheath Hematoma
        Adalimumab Induced Mononeuritis Multiplex in a Patient with Refractory Rheumatoid Arthritis: A Case Report
        Massive Pulmonary Emboli Associated with Olanzapine

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        FDA Looking for Grapefruit Interactions: Presented at ACCP

        By Roberta Friedman, PhD
        Special to DG News

        SAN FRANCISCO, CA -- September 23, 2002 -- The United States Food and Drug Administration (FDA) is mounting a search for more drugs that may have their metabolic disposition upset by concurrent consumption of grapefruit, according to a report here at the 31st Annual Meeting of the American College of Clinical Pharmacology (ACCP). Fifteen or more drugs already are labelled to reflect the grapefruit interaction.

        Dr. Toni Piazza-Hepp of the FDA presented a poster that included speculation on the way grapefruit interferes with drug absorption: by blocking cytochrome P450 in the intestine, or perhaps by active transporter systems such as the P-glycoprotein or organic anion transporter polypeptide. If a drug has a large first pass effect, consuming grapefruit could cause a higher drug dose to enter the bloodstream through any of these actions.

        Two drugs Dr. Piazza-Hepp cited as coming recently under suspicion are amlodipine, a calcium channel blocker, and atorvastatin, a cholesterol-lowering agent. These drugs are not currently labelled to warn of an interaction, but "it looks like the data are warranting looking further" at the possibility of an interaction, he said. Reports in the literature, as well as in the FDA-maintained database of adverse event reporting, suggest these and other drugs could have a grapefruit interaction.

        Clinicians have various options if a drug shares metabolic routes with grapefruit. If a patient is stabilised already on a particular drug, it may not be in the patient's best interest to switch. On the other hand, a patient may want to retain grapefruit in the diet. In any case, said Dr. Piazza-Hepp, "our job is to make sure that the information appears in the labelling to make a good prescribing decision possible."



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send